| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Analysts' ratings for Zimmer Biomet Holdings (NYSE:ZBH) over the last quarter vary from bullish to bearish, as provided by 10 analysts.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 0 | 4 | 6 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 0 | 1 | 2 | 0 | 0 |
| 2M Ago | 0 | 1 | 1 | 0 | 0 |
| 3M Ago | 0 | 1 | 3 | 0 | 0 |
In the assessment of 12-month price targets, analysts unveil insights for Zimmer Biomet Holdings, presenting an average target of $128.8, a high estimate of $140.00, and a low estimate of $115.00. Highlighting a 6.74% decrease, the current average has fallen from the previous average price target of $138.11.
A clear picture of Zimmer Biomet Holdings's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Shagun Singh | RBC Capital | Raises | Outperform | $140.00 | $134.00 |
| Vijay Kumar | Evercore ISI Group | Lowers | In-Line | $125.00 | $135.00 |
| Jayson Bedford | Raymond James | Raises | Outperform | $137.00 | $133.00 |
| Richard Newitter | Truist Securities | Raises | Hold | $133.00 | $115.00 |
| Cecilia Furlong | Morgan Stanley | Raises | Equal-Weight | $125.00 | $120.00 |
| David Turkaly | JMP Securities | Lowers | Market Outperform | $140.00 | $160.00 |
| Jayson Bedford | Raymond James | Lowers | Outperform | $133.00 | $160.00 |
| Cecilia Furlong | Morgan Stanley | Lowers | Equal-Weight | $120.00 | $140.00 |
| Robbie Marcus | JP Morgan | Lowers | Neutral | $115.00 | $146.00 |
| Jason Wittes | Roth MKM | Announces | Neutral | $120.00 | - |
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Zimmer Biomet Holdings's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
Stay up to date on Zimmer Biomet Holdings analyst ratings.
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two thirds of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Zimmer Biomet Holdings's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 5.02% as of 30 September, 2023, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Zimmer Biomet Holdings's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of 9.28%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Zimmer Biomet Holdings's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 1.31%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Zimmer Biomet Holdings's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 0.77%, the company may face hurdles in achieving optimal financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.45.
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: ZBH
